LYRIC/AEG1 Antibody (Rabbit mAb) [E12A5]

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IP1:30 IHC1:2000 IF1:100 FCM1:500

Application
WB, IP, IHC, IF, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
64 kDa 75 kDa,80 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
LYRIC/AEG1 Antibody (Rabbit mAb) [E12A5] detects endogenous levels of total LYRIC/AEG1 protein.

Clone
E12A5

Synonym(s)
AEG1, LYRIC, MTDH, Protein LYRIC, 3D3/LYRIC, Astrocyte elevated gene-1 protein, Lysine-rich CEACAM1 co-isolated protein, Metadherin, Metastasis adhesion protein, AEG-1

Background
LYRIC/AEG1, also known as astrocyte elevated gene‑1 or metadherin (MTDH), is a multifunctional protein encoded by the MTDH gene that localizes to the endoplasmic reticulum, perinuclear region and nucleus, and acts as a scaffold and adaptor in signaling and transcriptional networks that drive oncogenesis, metastasis and therapy resistance. The protein is lysine-rich and predicted to contain transmembrane and coiled-coil segments that facilitate membrane association and protein–protein interactions, allowing LYRIC/AEG1 to assemble complexes with signaling molecules and transcriptional regulators rather than functioning as a classical enzyme. In hepatocellular carcinoma, LYRIC/AEG1 is markedly upregulated and shown by gain- and loss-of-function studies to positively regulate multiple hallmarks of HCC progression, including proliferation, angiogenesis, invasion and metastasis; genetic deletion of AEG‑1 in mice prevents DEN-induced hepatocarcinogenesis by blocking NF‑κB activation, dampening inflammatory and survival gene expression and reducing tumor burden, indicating that LYRIC/AEG1 is required for carcinogen-driven liver tumor initiation and progression. Mechanistically, LYRIC/AEG1 activates several pathways relevant to HCC, including NF‑κB, PI3K/Akt and Wnt/β‑catenin signaling: overexpression enhances NF‑κB nuclear activity and upregulates angiogenesis- and chemoresistance-associated genes, and clinical studies link high AEG‑1 expression with increased β‑catenin, c‑Myc and cyclin D1, supporting a role in transcriptional activation of proliferative and stemness programs. LYRIC/AEG1 also influences autophagy and apoptosis, and contributes to chemoresistance by upregulating MDR genes and survival pathways, so its expression level predicts response to chemotherapy and correlates with poor prognosis in HCC cohorts. In breast cancer, AEG‑1/MTDH/LYRIC is a key functional target of recurrent 8q22 genomic gain seen in poor‑prognosis tumors, where it plays a dual role in promoting metastasis and chemoresistance; overexpression enhances tumor cell proliferation, adhesion, invasion, angiogenesis and survival under cytotoxic stress, while knockdown reduces metastatic spread and sensitizes cells to chemotherapeutic agents in xenograft models. Across multiple cancer types, clinicopathologic studies consistently show that high LYRIC/AEG1 expression associates with advanced stage, high-grade histology, increased microvessel density and hematogenous metastasis, and serum anti-AEG‑1 antibody titers can serve as predictors of aggressive disease, highlighting its potential as both tissue and blood-based biomarker. These data, together with evidence that LYRIC/AEG1 sits at the intersection of NF‑κB, PI3K/Akt, Wnt/β‑catenin and autophagy pathways and orchestrates gene-expression changes underlying proliferation, invasion, angiogenesis and chemoresistance, define LYRIC/AEG1 as a structurally adaptable and mechanistically central oncogenic regulator that is highly relevant for researchers evaluating signaling-driven tumor biology and exploring targeted interventions in liver, breast and other cancers.

Background

LYRIC/AEG1, also known as astrocyte elevated gene‑1 or metadherin (MTDH), is a multifunctional protein encoded by the MTDH gene that localizes to the endoplasmic reticulum, perinuclear region and nucleus, and acts as a scaffold and adaptor in signaling and transcriptional networks that drive oncogenesis, metastasis and therapy resistance. The protein is lysine-rich and predicted to contain transmembrane and coiled-coil segments that facilitate membrane association and protein–protein interactions, allowing LYRIC/AEG1 to assemble complexes with signaling molecules and transcriptional regulators rather than functioning as a classical enzyme. In hepatocellular carcinoma, LYRIC/AEG1 is markedly upregulated and shown by gain- and loss-of-function studies to positively regulate multiple hallmarks of HCC progression, including proliferation, angiogenesis, invasion and metastasis; genetic deletion of AEG‑1 in mice prevents DEN-induced hepatocarcinogenesis by blocking NF‑κB activation, dampening inflammatory and survival gene expression and reducing tumor burden, indicating that LYRIC/AEG1 is required for carcinogen-driven liver tumor initiation and progression. Mechanistically, LYRIC/AEG1 activates several pathways relevant to HCC, including NF‑κB, PI3K/Akt and Wnt/β‑catenin signaling: overexpression enhances NF‑κB nuclear activity and upregulates angiogenesis- and chemoresistance-associated genes, and clinical studies link high AEG‑1 expression with increased β‑catenin, c‑Myc and cyclin D1, supporting a role in transcriptional activation of proliferative and stemness programs. LYRIC/AEG1 also influences autophagy and apoptosis, and contributes to chemoresistance by upregulating MDR genes and survival pathways, so its expression level predicts response to chemotherapy and correlates with poor prognosis in HCC cohorts. In breast cancer, AEG‑1/MTDH/LYRIC is a key functional target of recurrent 8q22 genomic gain seen in poor‑prognosis tumors, where it plays a dual role in promoting metastasis and chemoresistance; overexpression enhances tumor cell proliferation, adhesion, invasion, angiogenesis and survival under cytotoxic stress, while knockdown reduces metastatic spread and sensitizes cells to chemotherapeutic agents in xenograft models. Across multiple cancer types, clinicopathologic studies consistently show that high LYRIC/AEG1 expression associates with advanced stage, high-grade histology, increased microvessel density and hematogenous metastasis, and serum anti-AEG‑1 antibody titers can serve as predictors of aggressive disease, highlighting its potential as both tissue and blood-based biomarker. These data, together with evidence that LYRIC/AEG1 sits at the intersection of NF‑κB, PI3K/Akt, Wnt/β‑catenin and autophagy pathways and orchestrates gene-expression changes underlying proliferation, invasion, angiogenesis and chemoresistance, define LYRIC/AEG1 as a structurally adaptable and mechanistically central oncogenic regulator that is highly relevant for researchers evaluating signaling-driven tumor biology and exploring targeted interventions in liver, breast and other cancers.

References
https://pubmed.ncbi.nlm.nih.gov/19221438/ https://pubmed.ncbi.nlm.nih.gov/23889989/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%